Chimerix, Inc. (NASDAQ:CMRX)

Chimerix, Inc. CMRX

Healthcare - Biotechnology - NASDAQ - US

Watchlist

$ 0.8599

-4.32 %

$ 77.3 M

Market Cap

-0.91

P/E

1. INTRINSIC VALUE

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy.[ Read More ]

The intrinsic value of one CMRX stock under the base case scenario is HIDDEN Compared to the current market price of 0.86 USD, Chimerix, Inc. is HIDDEN

CMRX Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart CMRX

FINANCIALS

Annual
Quarterly

324 K REVENUE

Growth Rates

1Year -99.04%

3Years -60.78%

5Years -46.24%

7Years -33.61%

10Years -22.91%

-93.1 M OPERATING INCOME

Growth Rates

1Year -54.12%

3Years -27.87%

5Years -5.38%

7Years -2.56%

10Years -12.52%

-82.1 M NET INCOME

Growth Rates

1Year -47.68%

3Years -23.56%

5Years -3.39%

7Years -1.03%

10Years -8.46%

-69.1 M OPERATING CASH FLOW

Growth Rates

1Year -47.41%

3Years -24.23%

5Years -5.16%

7Years -1.14%

10Years -10.46%

70.6 M INVESTING CASH FLOW

Growth Rates

1Year 0.80%

3Years 2.94%

5Years -7.65%

7Years -4.02%

10Years 22.26%

308 K FINANCING CASH FLOW

Growth Rates

1Year 102.42%

3Years -39.82%

5Years -51.25%

7Years -9.26%

10Years -44.25%

26 K REVENUE

Growth Rates

1Year -99.04%

3Years -60.78%

5Years -46.24%

7Years -33.61%

10Years -22.91%

-24.8 M OPERATING INCOME

Growth Rates

1Year -54.12%

3Years -27.87%

5Years -5.38%

7Years -2.56%

10Years -12.52%

-22.9 M NET INCOME

Growth Rates

1Year -47.68%

3Years -23.56%

5Years -3.39%

7Years -1.03%

10Years -8.46%

-20.3 M OPERATING CASH FLOW

Growth Rates

1Year -47.41%

3Years -24.23%

5Years -5.16%

7Years -1.14%

10Years -10.46%

28.3 M INVESTING CASH FLOW

Growth Rates

1Year 0.80%

3Years 2.94%

5Years -7.65%

7Years -4.02%

10Years 22.26%

-36 K FINANCING CASH FLOW

Growth Rates

1Year 102.42%

3Years -39.82%

5Years -51.25%

7Years -9.26%

10Years -44.25%

Balance Sheet Decomposition Chimerix, Inc.

213 M ASSETS
19.7 M LIABILITIES

Current Assets	189 M
Cash & Short-Term Investments	183 M
Receivables	1.14 M
Other Current Assets	5.14 M
Non-Current Assets	23.7 M
Long-Term Investments	21.7 M
PP&E	1.71 M
Other Non-Current Assets	301 K

Current Liabilities	18.4 M
Accounts Payable	2.85 M
Short-Term Debt	0
Other Current Liabilities	15.6 M
Non-Current Liabilities	1.3 M
Long-Term Debt	1.3 M
Other Non-Current Liabilities	0

EFFICIENCY

Earnings Waterfall Chimerix, Inc.

Revenue	324 K
Cost Of Revenue	0
Gross Profit	324 K
Operating Expenses	93.4 M
Operating Income	-93.1 M
Other Expenses	-11 M
Net Income	-82.1 M

RATIOS

100.00% GROSS MARGIN

Averages

1Year 100.00%

3Years 91.68%

5Years -101.38%

7Years -310.39%

10Years -493.25%

-28723.77% OPERATING MARGIN

Averages

1Year -28723.77%

3Years -12554.77%

5Years -7676.96%

7Years -5854.50%

10Years -4490.45%

-25337.96% NET MARGIN

Averages

1Year -25337.96%

3Years -12584.81%

5Years -7985.14%

7Years -6066.86%

10Years -4636.64%

-42.53% ROE

Averages

1Year -42.53%

3Years -116.76%

5Years -113.13%

7Years -90.96%

10Years -72.10%

-38.58% ROA

Averages

1Year -38.58%

3Years -77.12%

5Years -85.31%

7Years -70.45%

10Years -57.31%

-48.18% ROIC

Averages

1Year -48.18%

3Years -127.65%

5Years -84.53%

7Years -70.82%

10Years -57.98%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Chimerix, Inc.

Net Income	-82.1 M
Depreciation & Amortization	1 K
Capital Expenditures	-89 K
Stock-Based Compensation	17.5 M
Change in Working Capital	2.42 M
Others	-3.43 M
Free Cash Flow	-69.2 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Chimerix, Inc.

CMRX has no price targets from Wall Street.

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0 USD DIVIDEND PER SHARE

5. COMPETITION

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States.

1.09 USD

ASMB

Overvalued 93.24%

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

-0.715 USD

SPRO

Overvalued 160.61%

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.

3.18 USD

ACHL

Undervalued 202.40%

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL).

-11.6 USD

TIL

Overvalued 143.72%

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer.

-0.0407 USD

CTMX

Overvalued 104.48%

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.

0.233 USD

NXTC

Overvalued 82.24%

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

2.89 USD

DAWN

Overvalued 78.30%

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.

0.23 USD

XFOR

Overvalued 42.95%

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally.

-0.0218 USD

MREO

Overvalued 100.62%

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.

1.11 USD

TERN

Overvalued 81.96%

6. Ownership

Insider Ownership Chimerix, Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

1.06 K USD 1

6-9 MONTHS

6.61 K USD 3

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

16.5 K USD 1

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
3 months ago Aug 08, 2024	Sell 1.06 K USD	Andriole Michael T. PRESIDENT AND CEO	- 1285	0.8285 USD
9 months ago Feb 14, 2024	Sell 1.81 K USD	Andriole Michael T. PRESIDENT AND CEO	- 1744	1.0375 USD
9 months ago Feb 14, 2024	Sell 2.02 K USD	LaSpaluto Michelle CHIEF FINANCIAL OFFICER	- 1940	1.0426 USD
9 months ago Feb 14, 2024	Sell 2.78 K USD	Jakeman David VP OF FINANCE AND ACCOUNTING	- 2660	1.0439 USD
1 year ago Nov 17, 2023	Bought 16.5 K USD	MIDDLETON FRED A Director	+ 17295	0.9553 USD
1 year ago Nov 10, 2023	Bought 2.49 K USD	MIDDLETON FRED A Director	+ 2705	0.92 USD
1 year ago Sep 28, 2023	Sell 3.58 K USD	Jakeman David VP of Finance and Accounting	- 3610	0.9927 USD
1 year ago Sep 25, 2023	Bought 19.6 K USD	MIDDLETON FRED A Director	+ 20000	0.9818 USD
1 year ago May 18, 2023	Bought 59.1 K USD	Andriole Michael T. Chief Business Officer and CFO	+ 51700	1.1441 USD
1 year ago May 12, 2023	Bought 84.1 K USD	Sherman Michael A. Chief Executive Officer	+ 75015	1.1214 USD
1 year ago May 12, 2023	Bought 13.5 K USD	Sherman Michael A. Chief Executive Officer	+ 11985	1.1289 USD
1 year ago May 10, 2023	Bought 20 K USD	DEMSKI MARTHA J Director	+ 18000	1.11 USD
1 year ago May 08, 2023	Bought 9.98 K USD	Meyer Robert J. Director	+ 8750	1.14 USD
1 year ago Mar 28, 2023	Bought 24.2 K USD	MIDDLETON FRED A Director	+ 20000	1.2076 USD
1 year ago Jan 26, 2023	Sell 5.69 K USD	Jakeman David Principal Accounting Officer	- 3230	1.7605 USD
2 years ago Sep 29, 2022	Bought 37.2 K USD	MIDDLETON FRED A director:	+ 20000	1.8588 USD
2 years ago Sep 29, 2022	Sell 8.19 K USD	Jakeman David Principal Accounting Officer	- 4400	1.8603 USD
2 years ago May 19, 2022	Bought 40.7 K USD	MIDDLETON FRED A director:	+ 20000	2.0369 USD
2 years ago May 19, 2022	Bought 2.91 K USD	Meyer Robert J. director:	+ 1419	2.05 USD
2 years ago May 19, 2022	Bought 20.6 K USD	Meyer Robert J. Director	+ 9981	2.06 USD
2 years ago May 17, 2022	Bought 25.6 K USD	Andriole Michael T. Chief Business Officer and CFO	+ 15000	1.709 USD
2 years ago May 17, 2022	Bought 16.1 K USD	DEMSKI MARTHA J director:	+ 10000	1.61 USD
2 years ago Feb 04, 2022	Sell 18.4 K USD	Jakeman David Principal Accounting Officer	- 3300	5.5622 USD
3 years ago Sep 30, 2021	Sell 28.4 K USD	Jakeman David Principal Accounting Officer	- 4590	6.19 USD
3 years ago Sep 14, 2021	Sell 37.4 M USD	CANTEX PHARMACEUTICALS, INC. 10 percent owner	- 6500000	5.75 USD
3 years ago Jun 28, 2021	Bought 54.4 K USD	MIDDLETON FRED A Director	+ 6950	7.83 USD
3 years ago Jun 25, 2021	Bought 23.7 K USD	MIDDLETON FRED A Director	+ 3050	7.78 USD
3 years ago Apr 05, 2021	Sell 12.4 K USD	Jakeman David Principal Accounting Officer	- 1284	9.6786 USD
3 years ago Mar 01, 2021	Bought 14.7 K USD	Meyer Robert J. Director	+ 1500	9.8 USD
3 years ago Jan 28, 2021	Sell 27.6 K USD	Jakeman David Principal Accounting Officer	- 3211	8.611 USD
4 years ago Oct 02, 2020	Sell 10.6 K USD	Jakeman David Principal Accounting Officer	- 4270	2.48 USD
4 years ago Aug 19, 2020	Bought 10.2 K USD	Meyer Robert J. Director	+ 3500	2.92 USD
4 years ago Aug 10, 2020	Sell 5.15 K USD	DEMSKI MARTHA J Director	- 1584	3.2503 USD
4 years ago Aug 06, 2020	Sell 8.22 K USD	DEMSKI MARTHA J Director	- 2500	3.2895 USD
4 years ago Aug 07, 2020	Sell 8.12 K USD	DEMSKI MARTHA J Director	- 2500	3.25 USD
4 years ago Aug 05, 2020	Sell 8.19 K USD	DEMSKI MARTHA J Director	- 2500	3.2749 USD
4 years ago Aug 04, 2020	Sell 16.2 K USD	DEMSKI MARTHA J Director	- 5000	3.25 USD
4 years ago Mar 16, 2020	Bought 47.5 K USD	Andriole Michael T. Chief Business Officer	+ 33300	1.4271 USD
4 years ago Mar 12, 2020	Bought 106 K USD	Sherman Michael A. Chief Executive Officer	+ 72995	1.4474 USD
4 years ago Mar 12, 2020	Bought 106 K USD	Sherman Michael A. Chief Executive Officer	+ 72995	1.4474 USD
4 years ago Mar 12, 2020	Bought 69.9 K USD	MIDDLETON FRED A Director	+ 50000	1.398 USD
4 years ago Feb 07, 2020	Sell 4.34 K USD	Nichols Garrett Chief Medical Officer	- 2550	1.7 USD
4 years ago Feb 10, 2020	Sell 14.8 K USD	Nichols Garrett Chief Medical Officer	- 8805	1.6843 USD
4 years ago Feb 07, 2020	Sell 3.89 K USD	Jakeman David Principal Accounting Officer	- 2290	1.7 USD
4 years ago Jan 07, 2020	Sell 66 K USD	Nichols Garrett Chief Medical Officer	- 30680	2.1527 USD
5 years ago Nov 13, 2019	Bought 54.6 K USD	MIDDLETON FRED A Director	+ 30000	1.8189 USD
5 years ago Nov 11, 2019	Bought 33.2 K USD	MIDDLETON FRED A Director	+ 20000	1.6595 USD
5 years ago Nov 06, 2019	Bought 156 K USD	Andriole Michael T. Chief Business Officer	+ 100000	1.56 USD
5 years ago Nov 06, 2019	Bought 15.8 K USD	Meyer Robert J. Director	+ 10000	1.5797 USD
5 years ago May 28, 2019	Bought 64.8 K USD	DEMSKI MARTHA J Director	+ 18000	3.6 USD
5 years ago May 20, 2019	Bought 104 K USD	Sherman Michael A. Chief Executive Officer	+ 30000	3.4772 USD
5 years ago May 20, 2019	Bought 104 K USD	Sherman Michael A. Chief Executive Officer	+ 30000	3.4772 USD
5 years ago May 10, 2019	Bought 87.7 K USD	MIDDLETON FRED A Director	+ 30000	2.9226 USD
6 years ago Jun 12, 2018	Bought 45 K USD	Berrey M Michelle President and CEO	+ 10000	4.5015 USD
6 years ago May 17, 2018	Sell 144 K USD	MARIO ERNEST Director	- 30000	4.7977 USD
6 years ago May 18, 2018	Sell 72.1 K USD	MARIO ERNEST Director	- 15000	4.8095 USD
6 years ago May 16, 2018	Sell 144 K USD	MARIO ERNEST Director	- 30000	4.7936 USD
6 years ago May 15, 2018	Sell 141 K USD	MARIO ERNEST Director	- 30000	4.6936 USD
6 years ago May 11, 2018	Sell 32.6 K USD	MARIO ERNEST Director	- 7143	4.5659 USD
6 years ago May 11, 2018	Sell 106 K USD	MARIO ERNEST Director	- 22857	4.6273 USD
6 years ago May 14, 2018	Sell 105 K USD	MARIO ERNEST Director	- 22553	4.666 USD
6 years ago May 10, 2018	Sell 12.9 K USD	MARIO ERNEST Director	- 2815	4.6 USD
6 years ago Dec 01, 2017	Sell 88.7 K USD	Richardson Linda M Chief Commercial Officer	- 19833	4.471 USD
7 years ago Dec 27, 2016	Sell 337 K USD	MARIO ERNEST Director	- 72073	4.6778 USD
7 years ago Dec 27, 2016	Sell 16.9 K USD	MARIO ERNEST Director	- 3636	4.65 USD
7 years ago Dec 28, 2016	Sell 18.7 K USD	MARIO ERNEST Director	- 4000	4.6707 USD
7 years ago Dec 28, 2016	Sell 91.6 K USD	MARIO ERNEST Director	- 20291	4.516 USD
8 years ago Sep 15, 2016	Sell 25.2 K USD	LEONARD JOHN M. Director	- 5000	5.0325 USD
8 years ago Aug 29, 2016	Bought 100 K USD	Berrey M Michelle President and CEO	+ 22417	4.471 USD
8 years ago Jun 24, 2016	Bought 185 K USD	MARIO ERNEST Director	+ 50000	3.6969 USD
8 years ago Jun 24, 2016	Bought 48.6 K USD	Berrey M Michelle President and CEO	+ 13188	3.687 USD
8 years ago May 13, 2016	Bought 45.3 K USD	MARIO ERNEST Director	+ 10000	4.5328 USD
8 years ago May 11, 2016	Bought 117 K USD	MARIO ERNEST Director	+ 24200	4.8498 USD
8 years ago May 10, 2016	Bought 3.8 K USD	MARIO ERNEST Director	+ 800	4.755 USD
8 years ago Mar 16, 2016	Bought 23.9 K USD	MARIO ERNEST Director	+ 5000	4.7796 USD
8 years ago Mar 15, 2016	Bought 103 K USD	MARIO ERNEST Director	+ 20000	5.1314 USD
8 years ago Mar 01, 2016	Bought 46.1 K USD	WOLLAEGER TIMOTHY Director	+ 10000	4.61 USD
8 years ago Mar 01, 2016	Bought 48.9 K USD	DEMSKI MARTHA J Director	+ 10000	4.89 USD
8 years ago Dec 29, 2015	Bought 70.8 K USD	Machado Clarence Patrick Director	+ 10000	7.0846 USD
8 years ago Dec 29, 2015	Bought 887 K USD	MARIO ERNEST Director	+ 125000	7.0929 USD
9 years ago Nov 02, 2015	Sell 3.91 K USD	DEMSKI MARTHA J Director	- 100	39.07 USD
9 years ago Nov 02, 2015	Sell 4.05 K USD	DEMSKI MARTHA J Director	- 100	40.49 USD
9 years ago Nov 02, 2015	Sell 38.6 K USD	DEMSKI MARTHA J Director	- 926	41.69 USD
9 years ago Oct 01, 2015	Sell 67.7 K USD	DEMSKI MARTHA J Director	- 1800	37.61 USD
9 years ago Oct 01, 2015	Sell 7.67 K USD	DEMSKI MARTHA J Director	- 200	38.35 USD
9 years ago Sep 01, 2015	Sell 75.1 K USD	DEMSKI MARTHA J Director	- 1562	48.1 USD
9 years ago Sep 01, 2015	Sell 21.2 K USD	DEMSKI MARTHA J Director	- 438	48.48 USD
9 years ago Aug 21, 2015	Bought 47.4 K USD	LEONARD JOHN M. Director	+ 1000	47.38 USD
9 years ago Aug 03, 2015	Sell 109 K USD	DEMSKI MARTHA J Director	- 2000	54.6138 USD
9 years ago Jul 17, 2015	Sell 1.4 M USD	Trost Timothy W. SVP, CFO & Secretary	- 28000	50 USD
9 years ago Jul 01, 2015	Sell 59.4 K USD	DEMSKI MARTHA J Director	- 1300	45.7 USD
9 years ago Jul 01, 2015	Sell 32.6 K USD	DEMSKI MARTHA J Director	- 700	46.63 USD
9 years ago Jun 01, 2015	Sell 83.2 K USD	DEMSKI MARTHA J Director	- 2000	41.5821 USD
9 years ago May 12, 2015	Bought 75.2 K USD	Ricciardi Lisa Director	+ 1950	38.54 USD
9 years ago May 01, 2015	Sell 69.4 K USD	DEMSKI MARTHA J Director	- 2000	34.71 USD
9 years ago Apr 01, 2015	Sell 62.5 K USD	DEMSKI MARTHA J Director	- 1700	36.78 USD
9 years ago Apr 01, 2015	Sell 11.2 K USD	DEMSKI MARTHA J Director	- 300	37.42 USD
9 years ago Mar 02, 2015	Sell 60 K USD	DEMSKI MARTHA J Director	- 1500	40 USD
9 years ago Mar 02, 2015	Sell 20.4 K USD	DEMSKI MARTHA J Director	- 500	40.7 USD
9 years ago Feb 02, 2015	Sell 76.8 K USD	DEMSKI MARTHA J Director	- 2000	38.3845 USD
9 years ago Jan 02, 2015	Sell 82.2 K USD	DEMSKI MARTHA J Director	- 2000	41.077 USD
10 years ago Nov 05, 2014	Bought 290 K USD	MARIO ERNEST Director	+ 10000	29 USD
10 years ago Nov 05, 2014	Bought 116 K USD	LEONARD JOHN M. Director	+ 4000	29 USD
10 years ago Sep 25, 2014	Sell 139 K USD	Trost Timothy W. Sr. Vice President and CFO	- 5000	27.7549 USD
10 years ago Aug 25, 2014	Sell 126 K USD	Trost Timothy W. Sr. Vice President and CFO	- 5000	25.1343 USD
10 years ago Sep 09, 2014	Sell 1.46 M USD	NIEDEL JAMES Director	- 51100	28.54 USD
10 years ago Sep 10, 2014	Sell 2.92 M USD	NIEDEL JAMES Director	- 97129	30.03 USD
10 years ago Sep 09, 2014	Sell 6.24 M USD	NIEDEL JAMES Director	- 217321	28.72 USD
10 years ago Sep 09, 2014	Sell 1.74 M USD	NIEDEL JAMES Director	- 58531	29.67 USD
10 years ago Sep 10, 2014	Sell 10.3 M USD	NIEDEL JAMES Director	- 347188	29.54 USD
10 years ago Sep 11, 2014	Sell 9.72 M USD	NIEDEL JAMES Director	- 328680	29.58 USD
10 years ago Sep 09, 2014	Sell 3.6 M USD	WOLLAEGER TIMOTHY director, 10 percent owner:	- 122950	29.2751 USD
10 years ago Sep 09, 2014	Sell 3.6 M USD	Sanderling Venture Partners V, LP 10 percent owner	- 122950	29.2751 USD
10 years ago Sep 05, 2014	Sell 183 K USD	Sanderling Venture Partners VI Co Investment Fund LP 10 percent owner	- 7735	23.6622 USD
10 years ago Sep 08, 2014	Sell 2.27 M USD	Sanderling Venture Partners VI Co Investment Fund LP 10 percent owner	- 92265	24.6099 USD
10 years ago Sep 05, 2014	Sell 183 K USD	WOLLAEGER TIMOTHY director, 10 percent owner:	- 7735	23.6622 USD
10 years ago Sep 08, 2014	Sell 2.27 M USD	WOLLAEGER TIMOTHY director, 10 percent owner:	- 92265	24.6099 USD
10 years ago Sep 05, 2014	Bought 232 K USD	MARIO ERNEST Director	+ 10000	23.1872 USD
10 years ago Aug 25, 2014	Sell 126 K USD	Trost Timothy W. Sr. Vice President and CFO	- 5000	25.1343 USD
10 years ago Jul 25, 2014	Sell 112 K USD	Trost Timothy W. See Remarks	- 5000	22.3524 USD
10 years ago Jun 25, 2014	Sell 114 K USD	Trost Timothy W. Sr. Vice President and CFO	- 5000	22.7394 USD
10 years ago May 27, 2014	Bought 142 K USD	MARIO ERNEST Director	+ 10000	14.22 USD
10 years ago May 27, 2014	Sell 87.1 K USD	Trost Timothy W. SVP and CFO	- 5000	17.4134 USD
10 years ago May 27, 2014	Bought 200 K USD	Berrey M Michelle See Remarks	+ 14065	14.22 USD
10 years ago Apr 25, 2014	Sell 93.3 K USD	Trost Timothy W. See Remarks	- 5000	18.665 USD

7. News

Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript Chimerix, Inc. (NASDAQ:CMRX ) Q3 2024 Earnings Call November 7, 2024 8:30 AM ET Company Participants Will O'Connor - Investor Relations Mike Andriole - President and Chief Executive Officer Josh Allen - Chief Scientific Officer Michelle LaSpaluto - Chief Financial Officer Allen Melemed - Chief Medical Officer Tom Riga - Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft - Jefferies Operator Good morning, ladies and gentlemen and welcome to the Chimerix Third Quarter 2024 Earnings Conference Call. I would now like to introduce you to your host for today's call, Will O'Connor from Stern Investor Relations. seekingalpha.com - 1 week ago

Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates Chimerix (CMRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago. zacks.com - 1 week ago

Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024 DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview. globenewswire.com - 2 weeks ago

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 130,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4). globenewswire.com - 4 weeks ago

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 150,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4). globenewswire.com - 2 months ago

Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates Chimerix (CMRX) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.21 per share a year ago. zacks.com - 3 months ago

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4). globenewswire.com - 4 months ago

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET. globenewswire.com - 5 months ago

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update – Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – globenewswire.com - 6 months ago

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024 DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview. globenewswire.com - 6 months ago

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4). globenewswire.com - 7 months ago

Chimerix: Tackling A Strong Unmet Need With Promising Data Chimerix, Inc. is a biotech company focused on developing novel treatments for high-grade glioma and other therapies. Their main clinical asset, doraviprone, has shown promising results in treating H3 K27M-mutated diffuse midline glioma. The company has a strong financial position with over $200 million in assets and a runway of 2+ years, making it an attractive investment for those with a longer-term outlook. seekingalpha.com - 8 months ago

8. Profile Summary

Chimerix, Inc. CMRX

COUNTRY US

INDUSTRY Biotechnology

MARKET CAP $ 77.3 M

Dividend Yield 0.00%

Description Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Contact 2505 Meridian Parkway, Durham, NC, 27713 https://www.chimerix.com

IPO Date April 11, 2013

Employees 72

Officers Dr. Michael A. Alrutz J.D., Ph.D. Senior Vice President, General Counsel & Corporate Secretary Mr. David Jakeman CPA Vice President of Accounting & Finance Mr. Thomas J. Riga Chief Operating & Commercial Officer Ms. Michelle LaSpaluto Chief Financial Officer Dr. Joshua E. Allen Ph.D. Chief Technology Officer Dr. Allen S. Melemed M.B.A., M.D. Chief Medical Officer Mr. Michael T. Andriole M.B.A. Chief Executive Officer, President & Director Dr. Roy W. Ware M.B.A., Ph.D. Chief Manufacturing Technology Officer

Price Chart CMRX

Chimerix, Inc. CMRX

Premium Plan

Unlimited Plan